Skip to main content
Equibles
ATEC logo

ATEC · Alphatec Holdings, Inc.

Track ATEC — free

Use ATEC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ATEC

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$9.75 +0.22 (+2.31%) At close · Aug 19
Market Cap
$1.47B
Shares
154.45M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$9.75 Open$9.53 Day$9.50–10.00 52W close$6.99–22.68 Avg vol 30d2.2M Short int13.8M · 8.9% float · 7.3d Short vol72% Last earningsAug 4, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 4

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 4, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Neutral Momentum Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −26%
      below
      Price vs 50-day avg +8%
      above
      RSI (14) 56
      neutral
      MACD trend Negative
      52-week position 18%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +21%
      trailing
      6-month return −30%
      trailing
      YTD return −54%
      this year
      Relative strength −42%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $9 › 200d $13 — 200d above 50d
      Institutional flow Distributing
      -8% holders QoQ · +39 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      8.93% of float · ▲ +0.3% MoM · 7.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      264 holders — mid 3-yr range
      Squeeze score 74
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth −15%
      Y/Y
      Gross margin 523%
      expanding
      EPS growth +15%
      Y/Y
      Free cash flow $2.8M
      Buyback $25.0M
      authorized
      Balance sheet $405.1M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 66%
      annualized · 1-yr
      Max drawdown −69%
      past year
      ATR 4.7%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 3 of last 3
      Latest guidance · from the 8-K filed Aug 4, 2026
      Total revenue · fiscal year 2026 Lowered $882M
      Jan 12, 2026 $890M changed to Aug 4, 2026 $882M
      prior FY $764.16M midpoint +15.4% Y/Y
      Surgical revenue · fiscal year 2026 Maintained $805M
      Jan 12, 2026 $805M changed to Aug 4, 2026 $805M
      EOS revenue · fiscal year 2026 Lowered $77M
      Jan 12, 2026 $85M changed to Aug 4, 2026 $77M
      Adjusted EBITDA · fiscal year 2026 Non-GAAP Raised $140M
      Jan 12, 2026 $130M changed to Aug 4, 2026 $140M
      Prior guidance period ended · from the 8-K filed Oct 30, 2025
      Total revenue · fiscal year ending December 31, 2025 $760M
      Surgical revenue · fiscal year ending December 31, 2025 $684M
      EOS revenue · fiscal year ending December 31, 2025 $76M
      Non-GAAP adjusted EBITDA · fiscal year ending December 31, 2025 $91M
      Guided vs delivered · last 3 settled
      Total revenue fiscal year ending December 31, 2025
      guided $760M
      $764.16M Beat +0.5%
      Total revenue 2024
      guided $595M
      $611.56M Beat +2.8%
      Total revenue full-year 2023
      guided $472M
      $482.26M Beat +2.2%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      2 · 4 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −26% Bearish
      Price vs 50-day avg
      +8% Bullish
      RSI (14)
      56 Neutral
      MACD trend
      Negative Bearish
      52-week position
      18% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $9 › 200d $13 — 200d above 50d
      Institutional flow Distributing
      -8% holders QoQ · +39 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      8.93% of float · ▲ +0.3% MoM · 7.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      264 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $7 Now $10 · 18% Range high $23
      vs 200-day avg -26% vs 50-day avg +8%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Case volume growth 20% Second Quarter 2026 —
      Net new surgeon users 24% Second Quarter 2026 —
      Non-GAAP adjusted EBITDA non-GAAP $36M Quarter Ended June 30, 2026 —
      Non-GAAP adjusted EBITDA margin non-GAAP 16.8% Quarter Ended June 30, 2026 —
      Adjusted EBITDA non-GAAP $33M fourth quarter 2025 —
      Adjusted EBITDA margin non-GAAP 16% fourth quarter 2025 —
      Free cash flow (Full Year) non-GAAP $3M full year 2025 —
      Free cash flow (Q4) non-GAAP $8M fourth quarter —
      Net new surgeon users (Full Year) 20% full year 2025 —
      Net new surgeon users (Q4) 23% fourth quarter —
      Surgical revenue growth (YoY) 21% fourth quarter —
      Average revenue per procedure growth 2% Full Year Ended December 31, 2025 —
      Cash balance $161M as of December 31, 2025 —
      Surgical volume growth 24% Full Year Ended December 31, 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      ATEC
      Alphatec Holdings, Inc.
      this stock
      		$1.47B -53.7% -15.4% — 8.9%
      ABT
      Abbott Laboratories
      		 $196.27B -8.7% +5.7% 31.6 1.3%
      SYK
      Stryker Corp
      		 $127.34B -3.3% +11.2% 34.4 2.2%
      MDT
      Medtronic plc
      		 $120.49B -2.0% +8.4% 25.2 1.4%
      BSX
      Boston Scientific Corp
      		 $73.14B -45.5% +12.5% 20.4 1.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      264
      % held
      76.3%
      Net QoQ
      -2.6M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      207
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      13.8M
      Days to cover
      7.3d
      Change
      +39.8K sh
      View
      Short Volume
      Short vol %
      72%
      As of
      Aug 19, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2.9K
      Value
      $25.1K
      As of
      Jul 28, 2026
      View
      Off-Exchange
      Off-exchange %
      36.4%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $101.7M
      Net income (FY)
      $-143.4M
      EPS diluted
      $-0.96
      View
      Buybacks
      Authorized
      $25.0M
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 4, 2026
      This year
      11
      View
      Proposed Sales
      Value
      $84.5K
      Shares
      8.2K
      Filed
      Aug 5, 2026
      View
      Exempt Offerings
      Offering
      $168.0M
      Filed
      Dec 31, 2020
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 4, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      ATEC +1.3% +21.0% -30.4% +2.4% -53.7%
      SPY -0.4% +2.9% +11.6% +3.0% +12.8%
      vs SPY +1.7% +18.1% -42.0% -0.5% -66.4%

      Capital returns

      Buyback program · as of Aug 3, 2021
      Authorized
      $25.00M
      Spent (derived)
      —
      Remaining
      —

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1350653 CUSIP 02081G201 13F (30d) 237 filings 236 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)